Ruthie Davi, vice president of statistics and regulatory innovation at Medidata, highlights the value of technology in rare ...

In this video interview, Marc Buyse, ScD, founder and CEO of IDDI, examines the most common threats to trial data reliability, including opaque methodologies, synthetic controls, and the limits of ...

As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more flexible, data-driven approaches that integrate prior knowledge, reduce sample ...

New infrastructure strengthens Africa-based clinical trial logistics, reducing costs and accelerating timelines for ...

Geroscience examines the underlying biology of aging to delay chronic diseases and extend the healthy years of human life.

Practice-changing data in endometrial cancer support checkpoint inhibitor–chemotherapy combinations, extending ...

This article explores multiplexing applications in biopharma and highlights key assay development factors to consider.

They live in our houses, drink our water and even sleep in our beds. Cats have become an integral part of many households and ...

With various challenges impacting the clinical supply chain, existing models are no longer fit-for-purpose and need to adapt.

Clinical trials are the cornerstone of drug innovation in modern medicine, providing a systematic, evidence-based framework for determining the efficacy and safety of treatments before they reach ...

A narrative review examines how generative AI tools such as large language models and vision-language models could assist precision oncology by interpreting genomic data, matching patients to clinical ...

Polyrizon Ltd. (Nasdaq: PLRZ) ('Polyrizon” or the 'Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the successful production of a ...